FindTrial
Sign In

The novel pathway and classification of Korean steatohepatitis progression

The mechanism according to occurrence and progression of non-alcoholic fatty liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003579
Enrollment
100
Registered
2019-03-04
Start date
2018-08-30
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Korea University Anam Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with abnormal serum AST or ALT or bilirubin levels for more than three months, who agreed to undergo liver tissue examination to determine the cause Person who voluntarily decided to participate in this clinical trial and signed the consent form

Exclusion criteria

Exclusion criteria: - Excessive drinker (male, state > 140g; female, state > 70g) - Drug users who may cause hepatotoxicity or statosis - Non-targeted liver cirrhosis patient - Patients suffering from malignant tumors/systemic diseases - Pregnant patient

Design outcomes

Primary

MeasureTime frame
Differences in RNA Expressions by NAFLD stage—

Secondary

MeasureTime frame
Differences in Non-invasive Test According to Regional Progress—

Countries

Korea, Republic of

Contacts

Public ContactTaeHyung Kim

Korea University Anam Hospital

lacid81@gmail.com+82-2-920-6555

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026